UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Holdings in Insulet Corporation $PODD

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Insulet Corporation (NASDAQ:PODD) by 2.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 773,361 shares of the medical instruments supplier’s stock after selling 21,986 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.12% of Insulet worth $117,744,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of PODD. Glenmede Investment Management LP grew its holdings in shares of Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after purchasing an additional 35 shares during the last quarter. Curi Capital LLC increased its holdings in Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after purchasing an additional 36 shares during the period. Great Lakes Advisors LLC increased its holdings in Insulet by 1.5% in the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after buying an additional 40 shares in the last quarter. Camarda Financial Advisors LLC raised its holdings in shares of Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC raised its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the last quarter.

Analysts Set New Price Targets

PODD has been the topic of several recent research reports. Evercore set a $180.00 price objective on shares of Insulet in a research note on Monday, July 6th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $205.00 target price on shares of Insulet in a research note on Wednesday, May 27th. Citigroup raised their price target on Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Sanford C. Bernstein reduced their price target on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $152.00 target price (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $195.40.

Insulet Trading Down 0.2%

Shares of NASDAQ:PODD opened at $148.38 on Wednesday. The firm has a market capitalization of $10.29 billion, a P/E ratio of 27.73, a P/E/G ratio of 1.17 and a beta of 1.08. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The business’s 50-day moving average is $154.74 and its 200 day moving average is $179.24. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s quarterly revenue was up 23.5% on a year-over-year basis. During the same quarter last year, the company posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts predict that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.